Year All2026202520242023202220212020 Mar 10, 2026 Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update PDF Version Feb 18, 2026 Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference PDF Version Feb 17, 2026 Q32 Bio Announces $10.5 Million Registered Direct Offering PDF Version Dec 01, 2025 Q32 Bio Sells Complement Inhibitor ADX-097 PDF Version Nov 13, 2025 Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update PDF Version Oct 21, 2025 Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata PDF Version Aug 28, 2025 Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference PDF Version Aug 06, 2025 Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update PDF Version Jun 25, 2025 Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer PDF Version May 08, 2025 Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update PDF Version
Mar 10, 2026 Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update PDF Version
Feb 18, 2026 Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference PDF Version
Nov 13, 2025 Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update PDF Version
Oct 21, 2025 Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata PDF Version
Aug 06, 2025 Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update PDF Version
Jun 25, 2025 Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer PDF Version
May 08, 2025 Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update PDF Version